CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting. Chimeric antigen receptor (CAR) T cells are genetically engineered using autologous patient lymphocytes a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2019-09-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Subjects: | |
| Online Access: | https://onco-hema.healthbooktimes.org/article/24395-cd19-directed-car-t-cells-treatment-in-a-patient-with-refractory-dlbcl-and-cns-involvement |